Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.964
Journals
JCM
Special Issues
Chronic Lymphocytic Leukemia and COVID-19: Scientific Achievements and Unmet Needs
share announcement

Special Issue "Chronic Lymphocytic Leukemia and COVID-19: Scientific Achievements and Unmet Needs"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".

Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 2308

Special Issue Editor

Dr. Monia Marchetti

E-Mail
Guest Editor
Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Interests: chronic lymphocytic leukemia; chronic myeloproliferative neoplasms; clinical practice guidelines; evidence-based medicine; cost-effectiveness analysis; COVID-19
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Infections are a major hurdle for patients with chronic lymphocytic leukemia (CLL) and SARS-CoV2 was a difficult test bench for many of them. The interaction of several host-related and virus-related factors may impact onto the clinical outcomes of COVID-19. Moreover, therapies for CLL, vaccines, antivirals and monoclonal antibodies against SARS-CoV2 may also modulate the outcome. The present issue is devoted to clinical reporting of clinical and laboratory data pertaining the current scenario of care for CLL patients in a persisting pandemic era. We invite cohort studies, systematic reviews and biologic studies to be submitted.

Dr. Monia Marchetti
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic lymphocytic leukemia
  • COVID-19
  • Ibrutinib
  • Venetoclax

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

get_app
Opinion
Unexpected CD5+ B Cell Lymphocytosis during SARS-CoV-2 Infection: Relevance for the Pathophysiology of Chronic Lymphocytic Leukemia
by
Andrea Nicola Mazzarello
,
Brisejda Koroveshi
,
Daniela Guardo
,
Lorella Lanza
,
Fabio Ghiotto
,
Silvia Bruno
and
Enrico Cappelli
J. Clin. Med. 2023, 12(3), 998; https://doi.org/10.3390/jcm12030998 - 28 Jan 2023
Viewed by 2115
Abstract
Recently, cases of fortuitous discovery of Chronic Lymphocytic Leukemia (CLL) during hospitalization for Coronavirus disease (COVID-19) have been reported. These patients did not show a monoclonal B cell expansion before COVID-19 but were diagnosed with CLL upon a sudden lymphocytosis that occurred during [...] Read more.
Recently, cases of fortuitous discovery of Chronic Lymphocytic Leukemia (CLL) during hospitalization for Coronavirus disease (COVID-19) have been reported. These patients did not show a monoclonal B cell expansion before COVID-19 but were diagnosed with CLL upon a sudden lymphocytosis that occurred during hospitalization. The (hyper)lymphocytosis during COVID-19 was also described in patients with overt CLL disease. Contextually, lymphocytosis is an unexpected phenomenon since it is an uncommon feature in the COVID-19 patient population, who rather tend to experience lymphopenia. Thus, lymphocytosis that arises during COVID-19 infection is a thought-provoking behavior, strikingly in contrast with that observed in non-CLL individuals. Herein, we speculate about the possible mechanisms involved with the observed phenomenon. Many of the plausible explanations might have an adverse impact on these CLL patients and further clinical and laboratory investigations might be desirable. Full article
(This article belongs to the Special Issue Chronic Lymphocytic Leukemia and COVID-19: Scientific Achievements and Unmet Needs)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop